Acrux gains US patents for method of drug delivery

The four US patents provide additional protection for systemic delivery of drugs in specific therapeutic areas, namely analgesics, hormones, anti-Parkinson’s agents and anti-emetics. These are “continuation in part” patents, related to a previous US patent granted to Acrux’s.

The new patents, which expire in February 2017, further extend the proprietary nature of Acrux’s transdermal drug delivery technology for a number of products in the current pipeline. They provide protection for transdermal drug delivery systems, in the specific therapy areas, that consist of an effective amount of physiologically active agent (e.g. a therapeutic drug), a dermal penetration enhancer which is a safe skin-tolerant sunscreen, and a volatile liquid. Acrux now has six patents granted in the USA.

Acrux CEO and managing director, Dr Igor Gonda said: “These new US patents provide additional protection for our products in our core areas of interest. Our patenting activity is at the heart of our business strategy to develop and commercialize patient-preferred patent-protected healthcare products for valuable global markets.”